Sanofi to buy hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug
赛诺菲将以22亿美元收购乙型肝炎疫苗制造商Dynavax；多发性硬化症药物获CRL

Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday.
两家公司周三表示，赛诺菲将以220亿美元现金收购Dynavax Technologies，以补充其疫苗产品组合。